GLP-1 Receptor Ligands

Product #


Biochem/physiol Actions

Add to Cart

E7019 Exendin-3 ≥97%  
E7144 Exendin-4 ≥97% Activates GLP-1 (glucagon-like peptide-1) receptors to increase intracellular cAMP in pancreatic acinar cells; has no effect on VIP receptors.
Exendin-4 mimics the activity of mammalian incretin hormone glucagon-like peptide 1 (GLP-1), and thus, functions in the control of glucose. This includes the secretion of insulin in a glucose dependent manner, negative regulation of high glucagon secretion, and increased duration of stomach emptying. In type 2 diabetes patients, this peptide can be administered subcutaneously for glycemic control, when metformin is unable to produce adequate results. It promotes the neogeneration and proliferation of β-cells, and thus aids in the regeneration of pancreas. It acts as a ligand to exendin receptor, and leads to an elevation of acinar cell cAMP levels.
E7269 Exendin Fragment 9-39 ≥95% (HPLC) GLP-1 (glucagon-like peptide-1) receptor antagonist. Competitive inhibitor of exendin-3 and exendin-4.
G8147 Glucagon-Like Peptide I Amide Fragment 7-36 human ≥97% (HPLC), powder GLP-1 (glucagon-like peptide 1) (7-36) amide is a potent insulinotropic peptide, which initiates the glucose-induced insulin release after meals or oral glucose intake. It has an anti-diabetogenic effect and thus, might have use in the treatment of non-insulin dependent diabetes mellitus.
G8166 Glucagon-Like Peptide 2 -Arg human trifluoroacetate salt >90% (HPLC), solid Glucagon-like peptide 2 (GLP-2) influences the functionality of gastrointestinal tract by participating in the feedback loop to the brain for the control of food intake. It also controls digestion and absorption, and has tropic effects post chemotherapy injury or surgical resection. This peptide is also responsible for epithelial cell proliferation of the small bowel. Studies in rats show that this peptide enhances the effects of the ileal-brake hormones, GLP-1 and peptide YY. It also negatively regulates gastrointestinal motility and secretion. Thus, it has potential as a therapeutic agent in short-bowel syndrome.
Glucagon-like peptide 2 is a neuropeptide that inhibits food intake when injected into the lateral ventricles of the brain and may mediate satiety. It is also a growth factor that stimulates proliferation and blocks apoptosis of intestinal epithelial cells.
G9416 Glucagon-Like Peptide 1 Fragment 7-37 human ≥96% (HPLC) Glucagon-Like Peptide 1 Fragment 7-37 human (GLP-1-(7-37)) interacts with the GLP-1 receptor (GLP-1r). It mediates insulin release by stimulating the cyclic AMP accumulation in islet cells GLP-l(7-37) is a potential therapeutic agent due to its insulin-secretagogue functionality.
G3265 Glucagon-Like Peptide I human ≥97% (HPLC) Glucagon-Like Peptide I (GLP1) controls the metabolism of glucose, by inducing the secretion of insulin and suppressing that of glucagon. Studies in Indonesian population show that reduced levels of this protein are linked with increased susceptibility to type 2 diabetes mellitus. Plasma levels of this hormone also show significant association with systolic and diastolic blood pressure levels.